Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

FDA “Grids” for more transparent risk/benefit decision. “The Pink Sheet”. May 3, 2010. http://www.elsevierbi.com/Publications/The-Pink-Sheet/72/018/FDA-Grids-For-More-Transparent-RiskBenefit-Decision?result=2&total=2&searchquery=%253fq%253dGrids%252520for%252520more%252520transparent%252520risk%25252fbenefit%252520decision. Accessed June 21, 2012.

Coplan

Noel

Levitan

Ferguson

Mussen

. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines [published online ahead of print December 15, 2010]. Clin Pharmacol Ther. doi:10.1038/clpt.2010.291.

Levitan

Andrews

Gilsenan

. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011;89(2):217–224.

Noel

Hermann

Levitan

Watson

Van Goor

Application of the Benefit-Risk Action Team (BRAT) framework in pharmaceutical R&D: results from a pilot program. Drug Information Journal. 2012;46(6):737–744.

Associate Editor’s Commentary: In Praise of a BRAT

Abstract

Get full access to this article

References